2359.HK 603259.SHG
Bayzed operates healthcare

Leading pharmaceutical research outsourcing company WuXi AppTec Co. Ltd. (2359.HK; 603259.SH), announced on Tuesday that it has agreed to transfer its entire equity stakes in Advanced Therapies and Oxford Genetics to U.S.-based private equity firm Altaris LLC for cash consideration. The two companies being sold are the U.S. and UK operating entities of WuXi AppTec’s cell and gene therapy division, WuXi Advanced Therapies.

Altaris is a New York-based private equity fund specializing in the healthcare sector, according to a report on the deal in financial media Caixin. WuXi AppTec said the deal would not significantly impact its performance or operations and would ensure uninterrupted services for patients urgently requiring WuXi Advanced Therapies’ cell therapy solutions.

The sale comes amid speculation fueled by the proposed U.S. Biosecure Act, which is expected to take effect next year. The act explicitly aims to “prevent foreign competitors from stealing sensitive U.S. genetic data and personal health information,” making WuXi Advanced Therapies’ business a primary target. That led to rumors that WuXi AppTec was considering divestments of some of its overseas operations.

WuXi Advanced Therapies is one of WuXi AppTec’s five core business units. During the first 11 months of this year, Advanced Therapies and Oxford Genetics generated approximately 980 million yuan ($134 million) in revenue, about 2.4% of the company’s most recent audited annual figure.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Switchbot, with DJI Godfather as its non-executive director, is seeking Hong Kong IPO and fanning up market interest

Switchbot taps market frenzy for robotic stocks

The maker of smart home-use robots has filed for a Hong Kong IPO, boasting a key elder of China’s high-tech gadget world as a major shareholder and non-executive director Key…
SICC makes substraits

Sinking SICC looks for lift from Hong Kong IPO

The maker of silicon carbide substrates has been cleared by China’s securities regulator to list in Hong Kong, even as its revenue began to contract in the first quarter Key…
A comeback listing three years after exiting the Hong Kong stock market, what is it about?

Checking out or checking in? Jin Jiang can’t decide

Three years after privatizing its Hong Kong-listed shares, storied hotelier Jin Jiang has rolled out plans to re-list on the city’s stock exchange Key Takeaways: Jin Jiang has applied to…